Berlin, Germany
CogniScent is a German-based startup that focuses on non-invasive and AI-driven early detection of Alzheimer's and Parkinson's. The company's slogan, "Non invasive and AI-driven early detection of Alzheimer's and Parkinson's," effectively captures their core mission. Founded in 2019, CogniScent's primary areas of operation include AI, Health Care, and Machine Learning.
CogniScent's groundbreaking approach involves the development of a novel, non-invasive, software-based test for early detection of Alzheimer's and Parkinson's. Leveraging machine learning, the startup aims to predict a personal risk score based on early risk factors and symptoms, with a focus on the role of smell disorders. This unique approach marks a significant advancement in the field of neurodegenerative disease detection and reflects the company's commitment to leveraging cutting-edge technology for the betterment of healthcare.
Despite the lack of specific information on the last investment and investors, CogniScent's innovative and potentially transformative impact on neurodegenerative disease diagnostics positions it as an intriguing prospect for venture capital consideration. The startup's emphasis on non-invasive techniques and AI-driven solutions aligns with current industry trends, making it a compelling candidate for investment opportunities within the rapidly evolving landscape of healthcare technology.
